O
OnKure
Biotech & Life Sciences · Boulder, United States · Founded 2011
Developing treatments for cancer MoreLess
OnKure Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of precision medicines for cancer. The company targets cancers with PI3Kα mutations, which are among the most common oncogenic mutations.
OnKure's business model revolves around the discovery and development of targeted oncology therapeutics. The company aims to create "best-in-class" treatments that are highly selective for mutations, which could lead to better efficacy and fewer side effects for patients. The company is publicly traded on Nasdaq (OKUR) and recently completed a merger with Reneo Pharmaceuticals, along with a $65 million private placement, to fund its clinical trials and research and development activities. Its lead product candidate, OKI-219, is currently in a Phase 1b/2 clinical trial (PIKture-01) for the treatment of various solid tumors with PI3Kα mutations.
Keywords: biopharmaceutical, precision medicine, oncology, PI3Kα mutations, clinical-stage, targeted therapy, cancer treatment, drug development, solid tumors, oncogenic mutations
Company overview
OnKure company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- Boulder, United States
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 72.9
- Investment activity
- 1 companies · latest May 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
OnKure funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | May 2024 | $0 | — | Undisclosed | ↗ |
| LATE VCOther financing | Mar 2023 | $54M | $275M | Undisclosed | ↗ |
| SERIES BOther financing | Mar 2021 | $55M | $220M | Citadel · Samsara BioCapital · BlackRock · Cormorant Asset Management | — |
| DEBTDebt | Sep 2019 | $2M | — | Undisclosed | — |
| SERIES AOther financing | May 2018 | $7M | $28M | Delian Capital | — |
| SEEDOther financing | Jul 2015 | Undisclosed | — | ||
| SEEDOther financing | Mar 2013 | Undisclosed | — | ||
| GRANTOther financing | May 2012 | Undisclosed | — | ||
| ANGELOther financing | Oct 2011 | Undisclosed | — | ||
| SPINOUTOther financing | Jan 2011 | University of Colorado | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 41 |
| 2025 | 38 |
| 2024 | 38 |
| 2023 | 37 |
| 2022 | 31 |
| 2021 | 11 |
Growth signals
OnKure website traffic
Latest recorded traffic for OnKure is 2.6K monthly website visits, down 7.1% over the last three months. OnKure's team grew 7.9% over the past year.
Hiring
Open positions at OnKure
Current openings linked to this company in Dealroom.
Comparisons
OnKure compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
OnKure investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
OnKure's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where OnKure has talent and traffic
team presence
In the news
Latest news about OnKure
Recent press, funding announcements, and product moves mentioning OnKure — open to read from the original sources.
Market sentiment
What the market is saying about OnKure
An AI-synthesized read of the highest-engagement posts about OnKure on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OnKure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.